Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion
CONFIRMADO87% DE CONFIANZALilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".[1]
Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.
$3.8B
1.00